HMDB0002111 | Water | 7732-18-5 | | H2O | 18.0153 18.010564686 | Not Available |
HMDB0015248 | Trimethaphan | 7187-66-8 | | C22H25N2OS | 365.512 365.168759122 | - Nakamura K, Koide M, Imanaga T, Ogasawara H, Takahashi M, Yoshikawa M: Prolonged neuromuscular blockade following trimetaphan infusion. A case report and in vitro study of cholinesterase inhibition. Anaesthesia. 1980 Dec;35(12):1202-7. [PubMed:7457791 ]
|
HMDB0000910 | Tridecanoic acid | 638-53-9 | | C13H26O2 | 214.3443 214.193280076 | Not Available |
HMDB0015009 | Terbutaline | 23031-25-6 | | C12H19NO3 | 225.2842 225.136493479 | - Kovarik Z, Simeon-Rudolf V: Interaction of human butyrylcholinesterase variants with bambuterol and terbutaline. J Enzyme Inhib Med Chem. 2004 Apr;19(2):113-7. [PubMed:15449725 ]
|
HMDB0014526 | Tacrine | 321-64-2 | | C13H14N2 | 198.2637 198.115698458 | - Wang H, Tang XC: Anticholinesterase effects of huperzine A, E2020, and tacrine in rats. Zhongguo Yao Li Xue Bao. 1998 Jan;19(1):27-30. [PubMed:10375753 ]
- Krustev AD, Argirova MD, Getova DP, Turiiski VI, Prissadova NA: Calcium-independent tacrine-induced relaxation of rat gastric corpus smooth muscles. Can J Physiol Pharmacol. 2006 Nov;84(11):1133-8. [PubMed:17218977 ]
- Marco JL, Carreiras MC: Recent developments in the synthesis of acetylcholinesterase inhibitors. Mini Rev Med Chem. 2003 Sep;3(6):518-24. [PubMed:12871155 ]
- Ahmed M, Rocha JB, Correa M, Mazzanti CM, Zanin RF, Morsch AL, Morsch VM, Schetinger MR: Inhibition of two different cholinesterases by tacrine. Chem Biol Interact. 2006 Aug 25;162(2):165-71. Epub 2006 Jun 17. [PubMed:16860785 ]
|
HMDB0014535 | Sulpiride | 15676-16-1 | | C15H23N3O4S | 341.426 341.140926929 | - Vacca C, Maione S, Tozzi A, Marmo E: Benzamides and cholinesterases. Res Commun Chem Pathol Pharmacol. 1987 Feb;55(2):193-201. [PubMed:3823608 ]
- Dross K: [The relevance of anticholinesterase properties to toxicity and neuromuscular effects of sulpiride (author's transl)]. Arzneimittelforschung. 1977 Feb;27(2):404-6. [PubMed:577162 ]
|
HMDB0014347 | Succinylcholine | 306-40-1 | | C14H30N2O4 | 290.399 290.220557458 | - Ostergaard D, Engbaek J, Viby-Mogensen J: Adverse reactions and interactions of the neuromuscular blocking drugs. Med Toxicol Adverse Drug Exp. 1989 Sep-Oct;4(5):351-68. [PubMed:2682131 ]
|
HMDB0001897 | Substance P | 33507-63-0 | | C63H98N18O13S | 1347.63 1346.728146002 | - Lockridge O: Substance P hydrolysis by human serum cholinesterase. J Neurochem. 1982 Jul;39(1):106-10. [PubMed:6177830 ]
|
HMDB0000827 | Stearic acid | 57-11-4 | | C18H36O2 | 284.4772 284.271530396 | Not Available |
HMDB0015124 | Rivastigmine | 123441-03-2 | | C14H22N2O2 | 250.3367 250.168127958 | - Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
- Stahl SM: The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different. J Clin Psychiatry. 2000 Oct;61(10):710-1. [PubMed:11078030 ]
- Gottwald MD, Rozanski RI: Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer's disease: review and current status. Expert Opin Investig Drugs. 1999 Oct;8(10):1673-1682. [PubMed:11139819 ]
- Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE: Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD001191. doi: 10.1002/14651858.CD001191.pub2. [PubMed:19370562 ]
- Birks J: Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593. [PubMed:16437532 ]
- Naik RS, Hartmann J, Kiewert C, Duysen EG, Lockridge O, Klein J: Effects of rivastigmine and donepezil on brain acetylcholine levels in acetylcholinesterase-deficient mice. J Pharm Pharm Sci. 2009;12(1):79-85. [PubMed:19470293 ]
- Smith DA: Treatment of Alzheimer's disease in the long-term-care setting. Am J Health Syst Pharm. 2009 May 15;66(10):899-907. doi: 10.2146/ajhp070622. [PubMed:19420308 ]
- Bassil N, Grossberg GT: Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease. CNS Drugs. 2009;23(4):293-307. [PubMed:19374459 ]
- Lalli S, Albanese A: Rivastigmine in Parkinson's disease dementia. Expert Rev Neurother. 2008 Aug;8(8):1181-8. doi: 10.1586/14737175.8.8.1181. [PubMed:18671661 ]
- Onor ML, Trevisiol M, Aguglia E: Rivastigmine in the treatment of Alzheimer's disease: an update. Clin Interv Aging. 2007;2(1):17-32. [PubMed:18044073 ]
- Farlow MR: Update on rivastigmine. Neurologist. 2003 Sep;9(5):230-4. [PubMed:14587496 ]
- Greig NH, Lahiri DK, Sambamurti K: Butyrylcholinesterase: an important new target in Alzheimer's disease therapy. Int Psychogeriatr. 2002;14 Suppl 1:77-91. [PubMed:12636181 ]
|
HMDB0014324 | Ramipril | 87333-19-5 | | C23H32N2O5 | 416.5106 416.231122144 | - Shah GB, Sharma S, Mehta AA, Goyal RK: Oculohypotensive effect of angiotensin-converting enzyme inhibitors in acute and chronic models of glaucoma. J Cardiovasc Pharmacol. 2000 Aug;36(2):169-75. [PubMed:10942157 ]
|
HMDB0013930 | R-95913 | | | C18H18FNO2S | 331.404 331.10422772 | - Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
|
HMDB0014685 | Pyridostigmine | 155-97-5 | | C9H13N2O2 | 181.2117 181.09770267 | - Somani SM, Husain K, Asha T, Helfert R: Interactive and delayed effects of pyridostigmine and physical stress on biochemical and histological changes in peripheral tissues of mice. J Appl Toxicol. 2000 Jul-Aug;20(4):327-34. [PubMed:10942908 ]
- Servatius RJ, Ottenweller JE, Guo W, Beldowicz D, Zhu G, Natelson BH: Effects of inescapable stress and treatment with pyridostigmine bromide on plasma butyrylcholinesterase and the acoustic startle response in rats. Physiol Behav. 2000 May;69(3):239-46. [PubMed:10869589 ]
- Abou-Donia MB, Wilmarth KR, Abdel-Rahman AA, Jensen KF, Oehme FW, Kurt TL: Increased neurotoxicity following concurrent exposure to pyridostigmine bromide, DEET, and chlorpyrifos. Fundam Appl Toxicol. 1996 Dec;34(2):201-22. [PubMed:8954750 ]
|
HMDB0014859 | Procaine | 59-46-1 | | C13H20N2O2 | 236.3101 236.152477894 | - Perez-Guillermo F, Delgado EM, Vidal CJ: Inhibition of human serum and rabbit muscle cholinesterase by local anesthetics. Biochem Pharmacol. 1987 Nov 1;36(21):3593-6. [PubMed:3675616 ]
- Dorokhov KE, Grigorian GL: [Binding of reversible spin-labeled inhibitors with an butyrylcholinesterase active center]. Biofizika. 1986 Sep-Oct;31(5):746-51. [PubMed:3022829 ]
|
HMDB0015169 | Procainamide | 51-06-9 | | C13H21N3O | 235.3253 235.168462309 | - Bailey DN: Amitriptyline and procainamide inhibition of cocaine and cocaethylene degradation in human serum in vitro. J Anal Toxicol. 1999 Mar-Apr;23(2):99-102. [PubMed:10192412 ]
- Page JD, Wilson IB, Silman I: Butyrylcholinesterase: inhibition by arsenite, fluoride, and other ligands, cooperativity in binding. Mol Pharmacol. 1985 Apr;27(4):437-43. [PubMed:3982389 ]
|
HMDB0014871 | Pralidoxime | 6735-59-7 | | C7H9N2O | 137.1592 137.07148792 | - Pohanka M, Jun D, Kuca K: In vitro reactivation of trichlorfon-inhibited butyrylcholinesterase using HI-6, obidoxime, pralidoxime and K048. J Enzyme Inhib Med Chem. 2009 Jun;24(3):680-3. doi: 10.1080/14756360802328315. [PubMed:18825528 ]
- Khan S, Hemalatha R, Jeyaseelan L, Oommen A, Zachariah A: Neuroparalysis and oxime efficacy in organophosphate poisoning: a study of butyrylcholinesterase. Hum Exp Toxicol. 2001 Apr;20(4):169-74. [PubMed:11393267 ]
|
HMDB0015431 | Pipecuronium | 68399-58-6 | | C35H62N4O4 | 602.8912 602.477106492 | - Simon G, Biro K, Karpati E, Tuba Z: The effect of the steroid muscle relaxant pipecurium bromide on the acetylcholinesterase activity of red blood cells in vitro. Arzneimittelforschung. 1980;30(2a):360-3. [PubMed:6248079 ]
|
HMDB0014928 | Perindopril | 107133-36-8 | | C19H32N2O5 | 368.4678 368.231122144 | - Mehta A, Iyer L, Parmar S, Shah G, Goyal R: Oculohypotensive effect of perindopril in acute and chronic models of glaucoma in rabbits. Can J Physiol Pharmacol. 2010 May;88(5):595-600. doi: 10.1139/y10-026. [PubMed:20555429 ]
|
HMDB0014329 | Pentagastrin | 5534-95-2 | | C37H49N7O9S | 767.891 767.331246891 | - Chernysheva SV, Iaremko EE: [Cholinergic and hormonal correlations in the regulation of the secretory function of the small intestine]. Fiziol Zh SSSR Im I M Sechenova. 1983 Jun;69(6):827-31. [PubMed:6873393 ]
|
HMDB0000826 | Pentadecanoic acid | 1002-84-2 | | C15H30O2 | 242.3975 242.224580204 | Not Available |
HMDB0015430 | Pancuronium | 15500-66-0 | | C35H60N2O4 | 572.8619 572.455308418 | - Stovner J, Oftedal N, Holmboe J: The inhibition of cholinesterases by pancuronium. Br J Anaesth. 1975 Sep;47(9):949-54. [PubMed:1191483 ]
|
HMDB0000220 | Palmitic acid | 57-10-3 | | C16H32O2 | 256.4241 256.240230268 | Not Available |
HMDB0015029 | Oxybuprocaine | 99-43-4 | | C17H28N2O3 | 308.4158 308.209992772 | - Draeger J, Schloot W, Wirt H: Interindividual differences of corneal sensitivity. Genetic aspects. Ophthalmic Paediatr Genet. 1985 Aug;6(1-2):291-5. [PubMed:4069587 ]
- Dubbels R, Schloot W: Studies on the metabolism of benoxinate by human pseudocholinesterase. Metab Pediatr Syst Ophthalmol. 1983;7(1):37-43. [PubMed:6621359 ]
|
HMDB0014723 | Nizatidine | 76963-41-2 | | C12H21N5O2S2 | 331.457 331.113666321 | - Laine-Cessac P, Turcant A, Premel-Cabic A, Boyer J, Allain P: Inhibition of cholinesterases by histamine 2 receptor antagonist drugs. Res Commun Chem Pathol Pharmacol. 1993 Feb;79(2):185-93. [PubMed:8095733 ]
|
HMDB0015472 | Neostigmine | 59-99-4 | | C12H19N2O2 | 223.2915 223.144652862 | - Saito S: Cholinesterase inhibitors induce growth cone collapse and inhibit neurite extension in primary cultured chick neurons. Neurotoxicol Teratol. 1998 Jul-Aug;20(4):411-9. [PubMed:9697967 ]
|